Adenocarcinoma Trials in Madrid, Spain
Conditions / Adenocarcinoma / Madrid, Spain
Research into Adenocarcinoma spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | COMPLETED | PHASE2 |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | RECRUITING | — |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | TERMINATED | PHASE3 |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | TERMINATED | PHASE2 |
| NCT02183870 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | COMPLETED | PHASE2 |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | COMPLETED | PHASE3 |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | COMPLETED | PHASE2 |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT01009593 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | TERMINATED | PHASE3 |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | RECRUITING | — |